Vega-Magaña, N.; Muñoz-Valle, J.F.; Peña-RodrÃguez, M.; Viera-Segura, O.; Pereira-Suárez, A.L.; Hernández-Bello, J.; GarcÃa-Chagollan, M.
Specific T-Cell Immune Response to SARS-CoV-2 Spike Protein over Time in Naïve and SARS-CoV-2 Previously Infected Subjects Vaccinated with BTN162b2. Vaccines 2022, 10, 1117.
https://doi.org/10.3390/vaccines10071117
AMA Style
Vega-Magaña N, Muñoz-Valle JF, Peña-RodrÃguez M, Viera-Segura O, Pereira-Suárez AL, Hernández-Bello J, GarcÃa-Chagollan M.
Specific T-Cell Immune Response to SARS-CoV-2 Spike Protein over Time in Naïve and SARS-CoV-2 Previously Infected Subjects Vaccinated with BTN162b2. Vaccines. 2022; 10(7):1117.
https://doi.org/10.3390/vaccines10071117
Chicago/Turabian Style
Vega-Magaña, Natali, José Francisco Muñoz-Valle, Marcela Peña-RodrÃguez, Oliver Viera-Segura, Ana Laura Pereira-Suárez, Jorge Hernández-Bello, and Mariel GarcÃa-Chagollan.
2022. "Specific T-Cell Immune Response to SARS-CoV-2 Spike Protein over Time in Naïve and SARS-CoV-2 Previously Infected Subjects Vaccinated with BTN162b2" Vaccines 10, no. 7: 1117.
https://doi.org/10.3390/vaccines10071117
APA Style
Vega-Magaña, N., Muñoz-Valle, J. F., Peña-RodrÃguez, M., Viera-Segura, O., Pereira-Suárez, A. L., Hernández-Bello, J., & GarcÃa-Chagollan, M.
(2022). Specific T-Cell Immune Response to SARS-CoV-2 Spike Protein over Time in Naïve and SARS-CoV-2 Previously Infected Subjects Vaccinated with BTN162b2. Vaccines, 10(7), 1117.
https://doi.org/10.3390/vaccines10071117
